Vivimed Labs Limited Initiates Corporate Insolvency Resolution Process
Vivimed Labs Limited has initiated its Corporate Insolvency Resolution Process (CIRP) with the publication of Form G. The company has manufacturing facilities across India and reported revenue from operations of ₹103.60 crore for FY 2025-26. The last date for expressions of interest is June 29, 2026.
The CIRP process can lead to significant restructuring, change in management, and potentially the acquisition or liquidation of the company, thus having a high impact on its stakeholders.
The initiation of a Corporate Insolvency Resolution Process (CIRP) is a significant negative event for a company, indicating severe financial distress.
Vivimed Labs Limited has announced the publication of Form G, marking a step in the Corporate Insolvency Resolution Process (CIRP).
This announcement, dated June 16, 2026, follows the publication of Form G on June 14, 2026, in various newspapers as per SEBI regulations. The company is undergoing CIRP under the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016.
The Form G provides key details about Vivimed Labs Limited, including its PAN (AAACV0600A) and CIN (L02411KA1988PLC009465). It outlines the locations of its manufacturing facilities in Hyderabad, Telangana; Uttarakhand; and Bidar, Karnataka, along with immovable property in Pydibheemavaram, Andhra Pradesh.
The installed capacities for main products are listed as: Tablets (300 Million), Capsules (580 Million), Topicals (71 Million), Orals (12 Million), and Nasal Sprays & Opthalmics (22.5 Million). For the last financial year, revenue from operations stood at ₹103.60 crore for FY 2025-26 and ₹136.80 crore for FY 2023-24, as per audited financial statements. The company notes that the statutory audit for the financial year ended March 31, 2026, is underway, and audited financials are not yet finalized. Revenue from operations for the nine months ended December 31, 2025, was ₹48.23 crore.
The company has 352 employees. The last date for receipt of expressions of interest is June 29, 2026. Key dates for the resolution process include the provisional list of applicants on July 9, 2026, the final list on July 24, 2026, and the submission of resolution plans by August 28, 2026.
Further details can be sought via email at: cirp.vivimedlabslimited@hotmail.com.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under corporate insolvency resolution process. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.